Preview

Научно-практическая ревматология

Расширенный поиск

Клеточные и молекулярные биомаркеры и потенциальные терапевтические мишени при системной красной волчанке

https://doi.org/10.14412/1995-4484-2016-206-218

Полный текст:

Аннотация

Системная красная волчанка (СКВ) является одним из наиболее тяжелых и прогностически неблагоприятных системных заболеваний соединительной ткани, поражающим преимущественно женщин детородного возраста. Проводившиеся в последнее время научные исследования способствовали более глубокому пониманию ее патогенеза, выявлению и определению роли цитокинов, клеток и межклеточных связей, участвующих в развитии СКВ. Эти данные учитываются при разработке новых генно-инженерных биологических препаратов, действие которых направлено на ингибирование мишеней, участвующих в развитии заболевания. Эта информация позволяет также лучше понять механизм действия уже доказавших свою эффективность препаратов, таких как белимумаб и ритуксимаб. 

Об авторе

А. А. Меснянкина
ФГБНУ Научно-исследовательский институт ревматологии им. В.А. Насоновой, Москва
Россия

лаборатория интенсивных методов терапии

аспирант, младший научный сотрудник (научный руководитель – профессор С.К. Соловьев)



Список литературы

1. Насонов ЕЛ, Насонова ВА, редакторы. Ревматология: Национальное руководство. Москва: ГЭОТАР-Медиа; 2008 [Nasonov EL, Nasonova VA, editors. Revmatologiya: Natsional’noe rukovodstvo [Rheumatology: National guidelines]. Mosсow: GEOTAR-Media; 2008].

2. Dai С, Deng Y, Quinlan A, et al. Genetics of systemic lupus erythematosus: immune responses and end organ resistance to damage. Curr Opin Immunol. 2014;0:87-96. doi: 10.1016/j.coi.2014.10.004 PMC4274270

3. Dorner T. Deciphering the role of NETs and networks in SLE. Nat Rev Rheumatol. 2012;8(2):68-70. doi: 10.1038/nrrheum.2011.200

4. Palanichamy A, Bauer JW, Yalavarthi S, et al. Neutrophil mediated IFN activation in the bone marrow alters B cell development in human and murine SLE. J Immunol. 2014;192(3):906-18. doi: 10.4049/jimmunol.1302112. Epub 2013 Dec 30.

5. Jacobi AM, Odendahl M, Reiter K, et al. Correlation between circulating CD27(high) plasma cells and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum. 2003;48:1332- 42. doi: 10.1002/art.10949

6. Leandro MJ, Cambridge G, Edwards JC, et al. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology. 2005;44:1542-5. doi: 10.1093/rheumatology/kei080

7. Looney RJ, Anolik JH, Campbell D, et al. B cell depletion as a novel treatment for systemic lupus erythematosus a phase I/II dose-escalation trial of rituximab. Arthritis Rheum. 2004;50(8):2580-9. doi: 10.1002/art.20430

8. Stohl W, Hilbert DM. The discovery and development of belimumab: the anti-BLyS-lupus connection. Nat Biotechnol. 2012;30(1):69-77. doi: 10.1038/nbt.2076

9. Kim JM, Park SH, Kim HY, et al. A plasmacytoid dendritic cells type I interferon axis is critically implicated in the pathogenesis of systemic lupus erythematosus. Int J Mol. 2015;16:14158-70. doi: 10.3390/ijms160614158

10. Podolska MJ, Biermann MH, Mauerö der C, et al. Inflammatory etiopathogenesis of systemic lupus erythematosus: an update. J Inflamm Res. 2015;8:161-71. doi: 10.2147/JIR.S70325. eCollection 2015. Review.

11. Ma K, Li J, FangY, et al. Roles of B cell-intrinsic TLR signals in systemic lupus erythematosus. Int J Mol Sci. 2015;16:13084-105. doi: 10.3390/ijms160613084. Review.

12. Rönnblom LE, Alm GV, Oberg K. Autoimmune phenomena in patients with malignant carcinoid tumors during interferon-alpha treatment. Acta Oncol. 1991;30(4):537-40. doi: 10.3109/02841869109092414

13. Squatrito D, Emmi G, Silvestri E, et al. Pathogenesis and potential therapeutic targets in systemic lupus erythematosus: from bench to bedside. Auto Immun Highlights. 2014;5(2):33-45. doi: 10.1007/s13317-014-0058-y. eCollection 2014.

14. Dö rner T, Jacobi AM, Lipsky PE. B cells in autoimmunity. Review. Arthritis Res Ther. 2009;11:247. doi: 10.1186/ar2780. Epub 2009 Oct 14.

15. Александрова ЕН, Новиков АА, Соловьев СК и др. В- клетки при аутоиммунных ревматических заболеваниях. В кн.: Насонов ЕЛ, редактор. Анти-В-клеточная терапия в ревматологии: фокус на ритуксимаб. Москва: ИМА ПРЕСС; 2012. С. 8-45 [Alexandrova EN, Novikov AA, Soloviev SK, et al. B-cells in autoimmune rheumatic diseases. In: Nasonov EL, editor. Anti-B-kletochnaja terapija v revmatologii: fokus na rituksimab [Anti-B-cell therapy in rheumatology: Focus on rituximab]. Moscow: IMA-PRESS; 2012. P. 8-45].

16. Halverson R, Torres RM, Pelanda R. Receptor editing is the main mechanism of B cell tolerance toward membrane antigens. Nature Immunology. 2004;5(60):645-50. doi: 10.1038/ni1076

17. Wardemann H, Yurasov S, Schaefer A, et al Predominant autoan￾tibody production by early human B cell precursors. Science. 2003;301(5638):1374-7. doi: 10.1126/science.1086907

18. Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003;349:1526-33. doi: 10.1056/NEJMoa021933

19. Chan OT, Hannum LG, Haberman AM, et al. A novel mouse with B cells but lacking serum antibody reveals an antibody–independ￾ent role for B cells in murine lupus. J Exp Med. 1999;189:1639-48. doi: 10.1084/jem.189.10.1639

20. Jacobi AM, Reiter K, Mackay M, et al. Activated memory B cell subsets correlate with disease activity in systemic lupus erythematosus. Arthritis Rheum. 2008;58:1762-73. doi: 10.1002/art.23498

21. Kraaij T, Huizinga TW, Rabelink TJ, et al. Belimumab after rituximab as maintenance therapy in lupus nephritis. Rheumatology. 2014;53:2122-4. doi: 10.1093/rheumatology/keu369. Epub 2014 Sep 8.

22. Wei C, Anolik J, Cappione A, et al. A new population of cells lacking expression of CD27 represents a notable component of the B cell memory compartment in systemic lupus erythematosus. J Immunol. 2007;178:6624-33. doi: 10.4049/jimmunol.178.10.6624

23. Tackey E, Lipsky PE, Illei GG. Rationale for interleukin-6 blockade in systemic lupus erythematosus. Lupus 2004;13:339-43. doi: 10.1191/0961203304lu1023oa

24. Avery DT, Kalled SL, Ellyard JI, et al. BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J Clin Invest. 2003;112(2):286-97. doi: 10.1172/JCI18025

25. Wei Yu Lin, Seshasayee D, Lee WP, et al. Dual B cell immunotherapy is superior to individual anti-CD20 depletion or BAFF blockade in murine models of spontaneous or accelerated lupus. Arthritis Rheum. 2015;67(1):215-24. doi: 10.1002/art.38907

26. Mak A, Kow NY. The pathology of T cells in systemic lupus erythematosus. J Immunol Res. 2014;2014:419029. doi: 10.1155/2014/419029. Epub 2014 Apr 23.

27. Shin MS, Lee N, Kang I. Effector T cell subsets in systemic lupus erythematosus: update focusing on Th17 cells. Curr Opin Rheumatol. 2011;23(5):444-8. doi: 10.1097/BOR.0b013e328349a255

28. Scalapino KJ, Tang Q, Bluestone JA, et al. Suppression of disease in New Zealand black/New Zealand white lupus-prone mice by adoptive transfer of ex vivo expanded regulatory T cells. J Immunol. 2006;177(3):1451-9. doi: 10.4049/jimmunol.177.3.1451

29. Торгашина АВ, Быковская СЮ, Соловьев СК и др. Т-регуляторные клетки при системной красной волчанке и ревматоидном артрите. Научно-практическая ревматология. 2009;47(3):50-9 [Torgashina AV, Biykovskaya SY, Soloviev SK, et al. T-regulatory cells in systemic lupus erythe￾matosus and rheumatoid arthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2009;47(3):50-9 (In Russ.)]. doi: 10.14412/1995-4484-2009-1313

30. Торгашина АВ. Взаимосвязь содержания Т-регуляторных клеток, уровня сывороточных аутоантител у больных системной красной волчанкой на фоне лечения ритуксимабом. Научно-практическая ревматология. 2009;47(2):3-9 [Torgashina AV. Relationship of T regulatory cells content, activity and serum autoantibodies level in patients with systemic lupus erythematosus receiving rituximab. Nauchno￾Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2009;47(2):3-9 (In Russ.)]. doi: 10.14412/1995-4484- 2009-452

31. Wen Z, Xu L, Xu W, et al. Interleukin-17 expression positively correlates with disease severity of lupus nephritis by increasing antidouble-stranded DNA antibody production in a lupus model induced by activated lymphocyte derived DNA. PLoS One. 2013;8(3):58161. doi: 10.1371/journal.pone.0058161. Epub 2013 Mar 5.

32. Thompson JS, Bixler SA, Qian F. BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science. 2001;293:2108-11. doi: 10.1126/science.1061965

33. Gras MP, Laabi Y, Linares-Cruz G, et al. BCMAp: an integral membrane protein in the Golgi apparatus of human mature B lymphocytes. Int Immunol. 1995;7:1093-106. doi: 10.1093/intimm/7.7.1093

34. Von Bulow GU, Bram RJ. NF-AT activation induced by a CAMLinteracting member of the tumor necrosis factor receptor superfam￾ily. Science. 1997;278:138-41. doi: 10.1126/science.278.5335.138

35. Yan M, Brady JR, Chan B, et al. Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency. Curr Biol. 2001;11:1547-52. doi: 10.1016/S0960-9822(01)00481-X

36. Mackay F, Figgett WA, Saulep D, et al. B-cell stage and contextdependent requirements for survival signals from BAFF and the B-cell receptor. Immunol Rev. 2010;237:205-25. doi: 10.1111/j.1600-065X.2010.00944.x

37. Treml JF, Hao Y, Stadanlick JE, et al. The BLyS family: toward a molecular understanding of B cell homeostasis. Cell Biochem Biophys. 2009;53(1):1-16. doi: 10.1007/s12013-008-9036-1. Epub 2008 Nov 26.

38. Супоницкая ЕВ, Александрова ЕН, Насонов ЕЛ. Клиническое значение BAFF/BLyS и APRIL при системной красной волчанке и ревматоидном артрите. Научно-практическая ревматология. 2014;52(5):545-52 [Suponitskya EV, Aleksandrova EN, Nasonov EL. Clinical significance of BAFF/BLyS and APRIL in systemic lupus erythematosus and rheumatoid arthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(5):545-52 (In Russ.)]. doi: 10.14412/1995-4484-2014-545-552

39. Mackay F, Woodcock SA, Lawton P, et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med. 1999;190(11):1697-710. doi: 10.1084/jem.190.11.1697

40. Khare SD, Sarosi I, Xia XZ, et al. Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. Proc Natl Acad Sci USA. 2000;97:3370-5. doi: 10.1073/pnas.97.7.3370

41. Gross JA, Johnston J, Mudri S, et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature. 2000;404:995-9. doi: 10.1038/35010115

42. Elbirt D, Asher I, Mahlab-Guri K, et al. BLyS levels in sera of patients with systemic lupus erythematosus: Clinical and Serological Correlation. IMAJ. 2014;16:491-6.

43. Stohl W, Metyas S, Tan SM, et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum. 2003;48(12):3475-86. doi: 10.1002/art.11354

44. Petri M, Stohl W, Chatham W, et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum. 2008;58(8):2453-9. doi: 10.1002/art.23678

45. Davidson A. The Rationale for BAFF Inhibition in Systemic Lupus Erythematosus. Curr Rheumatol Rep. 2012;14(4): 295–302. doi: 10.1007/s11926-012-0258-2

46. Scapini P, Hu Y, Chu CL, et al. Myeloid cells, BAFF, and IFN- {gamma} establish an inflammatory loop that exacerbates autoim￾munity in Lyn-deficient mice. J Exp Med. 2010;207:1757-73. doi: 10.1084/jem.20100086. Epub 2010 Jul 12.

47. Chang SK, Mihalcik SA, Jelinek DF. B lymphocyte stimulator regulates adaptive immune responses by directly promoting dendritic cell maturation. J Immunol. 2008;180:7394-403. doi: 10.4049/jimmunol.180.11.7394

48. Jacob CO, Guo S, Jacob N. Dispensability of APRIL to the devel￾opment of systemic lupus erythematosus in NZM 2328 mice. Arthritis Rheum. 2012;64(5):1610-9. doi: 10.1002/art.33458

49. Treamtrakanpon W, Tantivitayakul P, Benjachat T, et al. APRIL, a proliferation-inducing ligand, as a potential marker of lupus nephritis. Arthritis Res Ther. 2012;14(6):R252. doi: 10.1186/ar4095

50. Morel J, Hahne M. To target or not to target APRIL in systemic lupus erythematosus: that is the question! Arthritis Res Ther. 2013;15(1):107. doi: 10.1186/ar4160

51. Boghdadi G, Elewa EA. Increased serum APRIL differentially correlates with distinct cytokine profiles and disease activity in systemic lupus erythematosus patients. Rheumatol Int. 2014;34(9):1217-23. doi: 10.1007/s00296-014-3020-4. Epub 2014 Apr 21.

52. Yap DY, Lai KN. The role of cytokines in the pathogenesis of sys￾temic lupus erythematosus – from bench to bedside. Nephrology. 2013;18(4):243-55. doi: 10.1111/nep.12047

53. Iwano M, Dohi K, Hirata E. Urinary levels of IL-6 in patients with active lupus nephritis. Clin Nephrol.1993;40:16-21.

54. Tsai CY, Wu TH, Yu CL. Increased excretions of beta2- microglobulin, IL-6, and IL-8 and decreased excretion of Tamm-Horsfall glycoprotein in urine of patients with active lupus nephri￾tis. Nephron. 2000;85:207-14. doi: 10.1159/000045663

55. Gröndal G, Gunnarsson I, Rönnelid J, et al. Cytokine production, serum levels and disease activity in systemic lupus erythematosus. Clin Exp Rheumatol. 2000;18:565-70.

56. Reyes-Thomas J, Blanco I, Putterman C. Urinary biomarkers in lupus nephritis. Clin Rev Allergy Immunol. 2011;40(3):138-50. doi: 10.1007/s12016-010-8197-z

57. Ryffel B, Car BD, Gunn H, et al. Interleukin-6 exacerbates glomerulonephritis in (NZB x NZW)F1 mice. Am J Pathol. 1994;144:927-37.

58. Cash H, Relle M, Menke J, et al. Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: The IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus. J Rheumatol. 2010;37:60-70. doi: 10.3899/jrheum.090194. Epub 2009 Dec 1.

59. Mihara M, Takagi N, Takeda Y, et al. IL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB/W F1 mice. Clin Exp Immunol. 1998;112(3):397-402. doi: 10.1046/j.1365-2249.1998.00612.x

60. Finck BK, Chan B, Wofsy D. Interleukin 6 promotes murine lupus in NZB/NZW F1 mice. J Clin Invest. 1994;94:585-91. doi: 10.1172/JCI117373

61. Hirohata S, Kanai Y, Mitsuo A, et al. Accuracy of cerebrospinal fluid IL-6 testing for diagnosis of lupus psychosis. A multicenter retrospective study. Clin Rheumatol. 2009;28:1319-23. doi: 10.1007/s10067-009-1226-8. Epub 2009 Jul 12.

62. Trysberg E, Blennow K, Zachrisson O, et al. Intrathecal levels of matrix metalloproteinases in systemic lupus erythematosus with central nervous system engagement. Arthritis Res Ther. 2004;6:551-6. doi: 10.1186/ar1228. Epub: 2004 Sep 23.

63. Fragoso-Loyo H, Richaud-Patin Y, Orozco-Narvaez A. Interleukin-6 and chemokines in the neuropsychiatric manifestations of systemic lupus erythematosus. Arthritis Rheum. 2007;56(4):1242-50. doi: 10.1002/art.22451

64. Eilertsen GO, Nikolaisen C, Becker-Merok A, et al. Interleukin-6 promotes arthritis and joint deformation in patients with systemic lupus erythematosus. Lupus. 2011;20(6):607-13. doi: 10.1177/0961203310392432. Epub 2011 Mar 21.

65. Vasoo S, Hughes GRV. Perspectives on the changing face of lupus mortality. Autoimmun Rev. 2004;3:415-7. doi: 10.1016/j.autrev.2004.06.005

66. Pryor BD, Bologna SG, Kahl LE. Risk factors for serious infection during treatment with cyclophosphamide and high-dose corti￾costeroids for systemic lupus erythematosus. Arthritis Rheum. 1996;39:1475-82. doi: 10.1002/art.1780390906

67. Anolik JH, Barnard J, Cappione A. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum. 2004;50(11):3580-90. doi: 10.1002/art.20592

68. Левицки А, Линдео С, ван Волленховен РФ. Ритуксимаб в терапии системной красной волчанки. Научно-практическая ревматология. 2013;51(3):223-39 [Levitsky A, Linder S, van Vollenhoven RF. Rituximab in the management of systemic lupus erythematosus. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2013;51(3):223-39 (In Russ.)].

69. Ананьева ЛП, Соловьев СК, Бекетова ТВ и др. Анти-В- клеточная терапия при иммуновоспалительных ревматических заболеваниях: эффективность и переносимость у 229 больных. Научно-практическая ревматология. 2014;52(5):495-506 [Ananieva LP, Soloviyov SK, Beketova TV, et al. Anti-B-cell therapy at immune inflammatory rheumatic diseases: efficacy and tolerability in 229 patients. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(5):495-506 (In Russ.)]. doi: 10.14412/1995- 4484-2014-495-506

70. Асеева ЕА, Соловьев СК, Насонов ЕЛ. Генно-инженерные биологические препараты в терапии системной красной волчанки. Современная ревматология. 2013;7(3):33-40 [Aseeva EA, Solovyev SK, Nasonov EL. Genetically engineered biological agents in therapy for systemic lupus erythematosus. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2013;7(3):33-40 (In Russ.)]. doi: 10.14412/1996- 7012-2013-11

71. Paran D, Naparstek Y. Is B cell-targeted therapy effective in systemic lupus erythematosus? Isr Med Assoc J. 2015;17(2):98-103. Review.

72. Насонов ЕЛ, Соловьев СК. Перспективы фармакотерапии системной красной волчанки. Научно-практическая ревматология. 2014;52(3):311-21 [Nasonov EL, Solovyev SK. Prospects for pharmacotherapy of systemic lupus erythematosus. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(3):311-21 (In Russ.)]. doi: 10.14412/1995- 4484-2014-311-321

73. Townsend MJ, Monroe JG, Chan AC. B-cell targeted therapies in human autoimmune diseases: an updated perspective. Immunol Rev. 2010;237:264-83. doi: 10.1111/j.1600-065X.2010.00945.x

74. Roll P, Palanichamy A, Kneitz C, et al. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum. 2006;54:2377-86. doi: 10.1002/art.22019

75. Vital EM, Dass S, Buch MH, et al. B cell biomarkers of rituximab responses in systemic lupus erythematosus. Arthritis Rheum. 2011;63:3038-47. doi: 10.1002/art.30466

76. Tew GW, Rabbee N, Wolslegel K. Baseline autoantibody profiles predict normalization of complement and anti-dsDNA autoantibody levels following rituximab treatment in systemic lupus erythematosus. Lupus. 2010;19:146-57. doi: 10.1177/0961203309350752. Epub: 2009 Nov 27.

77. Albert D, Dunham J, Khan S, et al. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus. Ann Rheum Dis. 2008;67:1724-31. doi: 10.1136/ard.2007.083162. Epub: 2008 Feb 4.

78. Vigna-Perez M, Hernandez-Castro B, Paredes-Saharopulos O, et al. Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther. 2006;8:83. doi: 10.1186/ar1954. Epub: 2006 May 5

79. Illei GG, Shirota Y, Yarboro CH, et al. Tocilizumab in systemic lupus erythematosus – safety, preliminary efficacy, and impact on circulating plasma cells. Arthritis Rheum. 2010;62(2):542-52. doi: 10.1002/art.27221

80. Shirota Y, Yarboro C, Fischer R, et al. Impact of anti-interleukin- 6 receptor blockade on circulating T and B cell subsets in patients with systemic lupus erythematosus. Ann Rheum Dis. 2013;72(1):118-28. doi: 10.1136/annrheumdis-2012-201310. Epub 2012 Aug 2.

81. Vallerskog T, Gunnarsson I, Widhe M, et al. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin Immunol. 2007;122:62-74. doi: 10.1016/j.clim.2006.08.016. Epub 2006 Oct 13.

82. Anolik JH, Barnard J, Owen T, et al. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum. 2007;56:3044-56. doi: 10.1002/art.22810

83. Jacobi AM, Huang W, Wang T, et al. Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum. 2010;62(1):201-10. doi: 10.1002/art.27189

84. Baker KP, Edwards BM, Main SH, et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum. 2003;48:3253-65. doi: 10.1002/art.11299

85. Halpern WG, Lappin P, Zanardi T, et al. Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamics and toxicologic effects. Toxicol Sci. 2006;91:586-99. doi: 10.1093/toxsci/kfj148. Epub: 2006 Mar 3.

86. Насонов ЕЛ, Решетняк ТМ, Денисов ЛН и др. Белимумаб: прогресс в лечении системной красной волчанки. Научно-практическая ревматология. 2012;54(5):13-9 [Nasonov EL, Reshetnjak TM, Denisov LN, et al. Belimumab: advances in drug therapy for systemic lupus erythematosus. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2012;54(5):13-9 (In Russ.)].

87. Zouali M, Uy EA. Belimumab therapy in systemic lupus erythematosus. BioDrugs. 2013;27:225-35. doi: 10.1007/s40259-013- 0031-8

88. Huang W, Moisini I, Bethunaickan R, et al. BAFF/APRIL inhibition decreases selection of naive but not antigen-induced autoreactive B cells in murine systemic lupus erythematosus. J Immunol. 2011;187:6571-80. doi: 10.4049/jimmunol.1101784. Epub 2011 Nov 18.

89. Nikbakht N, Migone TS, Ward CP, et al. Cellular competition independent of BAFF/B lymphocyte stimulator results in low frequency of an autoreactive clonotype in mature polyclonal B cell compartments. J Immunol. 2011; 187:37-46. doi: 10.4049/jimmunol.1003924. Epub 2011 Jun 1.

90. Bekar KW, Owen T, Dunn R, et al. Prolonged effects of short-term anti-CD20 B cell depletion therapy in murine systemic lupus erythematosus. Arthritis Rheum. 2010;62:2443-57. doi: 10.1002/art.27515

91. Vallerskog T, Heimbü rger M, Gunnarsson I, et al. Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther. 2006;8:167. doi: 10.1186/ar2076

92. Lavie F, Miceli-Richard C, Ittah M, et al. Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production. Ann Rheum Dis. 2007;66:700-3. doi: 10.1136/ard.2006.060772. Epub 2006 Oct 13

93. Kamata Y, Minota S. Successful treatment of massive intractable pericardial effusion in a patient with systemic lupus erythematosus with tocilizumab. BMJ Case Rep. 2012. doi: 10.1136/bcr-2012- 007834

94. Mathian A, Hie M, Cohen-Aubart F, et al. Targeting interferons in systemic lupus erythematosus: current and future prospects. Drugs. 2015;75(8):835-46. doi: 10.1007/s40265-015-0394-x


Для цитирования:


Меснянкина А.А. Клеточные и молекулярные биомаркеры и потенциальные терапевтические мишени при системной красной волчанке. Научно-практическая ревматология. 2016;54(2):206-218. https://doi.org/10.14412/1995-4484-2016-206-218

For citation:


Mesnyankina A.A. CELLULAR AND MOLECULAR BIOMARKERS AND POTENTIAL THERAPEUTIC TARGETS IN SYSTEMIC LUPUS ERYTHEMATOSUS. Rheumatology Science and Practice. 2016;54(2):206-218. (In Russ.) https://doi.org/10.14412/1995-4484-2016-206-218

Просмотров: 281


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1995-4484 (Print)
ISSN 1995-4492 (Online)